SMMT Q3 2021 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+623.2% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$19M-1488.6% margin

Net Income

-$20M-1497.2% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+2196.5%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$129M

Total Liabilities

$26M

Stockholders' Equity

$102M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$181,000	+623.2%
Gross Profit	$1M	$181,000	+623.2%
Operating Income	-$19M	-$17M	-15.0%
Net Income	-$20M	-$18M	-10.7%

Revenue Segments

License and Service

$1M100%

Geographic Segments

Latin America

$1M100%